Allspring Global Investments Holdings LLC Has $26.39 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Allspring Global Investments Holdings LLC decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 273,661 shares of the biotechnology company's stock after selling 80,841 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.29% of Sarepta Therapeutics worth $26,389,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. International Assets Investment Management LLC boosted its stake in shares of Sarepta Therapeutics by 9,382.5% during the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company's stock worth $1,097,000 after buying an additional 11,259 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sarepta Therapeutics by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company's stock worth $1,044,000 after buying an additional 8,427 shares during the period. Fifth Third Bancorp boosted its stake in shares of Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company's stock worth $96,000 after buying an additional 924 shares during the period. Handelsinvest Investeringsforvaltning acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $302,000. Finally, DMC Group LLC boosted its stake in shares of Sarepta Therapeutics by 15.0% during the fourth quarter. DMC Group LLC now owns 3,793 shares of the biotechnology company's stock worth $366,000 after buying an additional 496 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Buying and Selling

In related news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Kathryn Jean Boor sold 761 shares of the company's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares of the company's stock, valued at approximately $923,941.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $1.58 during mid-day trading on Friday, reaching $122.87. 656,117 shares of the company's stock were exchanged, compared to its average volume of 590,725. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The company has a 50-day simple moving average of $127.46 and a two-hundred day simple moving average of $110.40. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a market cap of $11.54 billion, a price-to-earnings ratio of -20.08 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million during the quarter, compared to analysts' expectations of $387.18 million. During the same period last year, the company posted ($1.24) EPS. The company's revenue was up 53.6% on a year-over-year basis. On average, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. Cantor Fitzgerald reissued a "neutral" rating and set a $128.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Royal Bank of Canada increased their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. UBS Group increased their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating for the company in a report on Thursday, February 29th. Finally, Barclays increased their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $158.38.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.